Or Kakhlon and colleagues screened FDA-approved compounds for those able to reduce GYS activity and polyglucosan accumulation in APBD fibroblasts. Guaiacol emerged as a potential candidate from this screen and improved grip strength and increased lifespan in murine APBD models. These improvements corresponded with reduced polyglucosans in peripheral nerves, liver and heart. Together, these results support further exploration of guaiacol for treating APBD.
Download Paper | Appendix 1 | Appendix 2 | Appendix 3